Phase 2b clinical trial results of TC-5214 to be presented at nAChR2009

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today confirmed plans to present data from its completed Phase 2b clinical trial of TC-5214 as an augmentation treatment for major depressive disorder at the Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium (nAChR2009) in Lincolnshire, Illinois on October 15, 2009. Additionally, Targacept announced that data regarding AZD3480 (TC-1734) and TC-5619 are also scheduled to be presented at nAChR2009.

nAChR2009 is a satellite meeting of the 39th annual meeting of the Society for Neuroscience. The full agenda and registration information for nAChR2009 can be found at https://www.cmpinc.net/nicotinic/home.html.

The scheduled presentations include:

  • Title: “From MCI to ADHD: Targeting nAChRs for cognitive/attention disorders”
    Presenter: Paul Newhouse, University of Vermont College of Medicine
    Date/Time: October 15, 2009, 10:30 – 11:00 a.m. CDT

    Dr. Newhouse was co-Principal Investigator for the completed Phase 2 clinical study of AZD3480 in adults with attention deficit/hyperactivity disorder. Targacept announced positive top-line results from the study earlier this year.
  • Title: “Clinical Update: AZD3480 / TC-1734”
    Presenter: Edwin C. Johnson, Ph.D., AstraZeneca
    Date/Time: October 15, 2009, 11:30 a.m. – 12:00 noon CDT
  • Title: “TC-5619: An α7 nAChR selective agonist with efficacy in animal models of positive and negative symptoms, and cognitive dysfunction of schizophrenia”
    Presenter: Patrick M. Lippiello, Ph.D., Targacept, Inc.
    Date/Time: October 15, 2009, 2:00 –2:30 p.m. CDT
  • Title: “Positive effects of the nicotinic channel blocker TC-5214 as augmentation treatment in patients with major depressive disorder who are inadequate responders to a first-line SSRI”
    Presenter: Geoffrey C. Dunbar, M.D., Targacept, Inc.
    Date/Time: October 15, 2009, 5:00 – 5:30 p.m. CDT

http://www.targacept.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vitamin K2 reduces the frequency, intensity, and duration of nighttime leg cramps